M
Mustang Bio, Inc. (MBIO)
NCM – Real Time Price. Currency in USD
0.66
-0.00 (-0.27%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.66
-0.00 (-0.27%)
At close: May 12, 2026, 4:00 PM EDT
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
| Name | Position |
|---|---|
| Dr. Manuel Litchman M.D. | President, CEO, Interim CFO & Director |
| Mr. Greg Furrow M.S. | Chief Quality Officer |
| Mr. Michael S. Weiss Esq., J.D. | Executive Chairman |
| Mr. Peter Carney | Controller & Interim Chief Accounting Officer |
| Ms. Robyn M. Hunter | Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 10-Q | tmb-20260331x10q.htm |
| 2026-04-17 | 8-K | tm2612037d1_8k.htm |
| 2026-03-19 | 10-K | tmb-20251231x10k.htm |
| 2025-12-23 | 8-K | tmb-20251217x8k.htm |
| 2025-12-03 | DEF 14A | tmb-20251222xdef14a.htm |
| 2025-11-07 | 10-Q | tmb-20250930x10q.htm |
| 2025-08-08 | 10-Q | tmb-20250630x10q.htm |
| 2025-07-09 | 8-K | tm2520081d1_8k.htm |
| 2025-05-14 | 10-Q | tmb-20250331x10q.htm |
| 2025-04-04 | POS AM | tm2511481d1_posam.htm |